GE Healthcare has formed a global alliance with Theragnostics for the commercialisation of a prostate-specific membrane antigen (PSMA) PET / CT imaging agent, GalliProst.

The diagnostic is designed to help visualise prostate cancer, offering information on the status of the disease and allowing personalised treatment.

Under the agreement, Theragnostics will be responsible for the development of GalliProst, while GE Healthcare will lead pre and post-approval commercial activities along with distribution activities.

The diagnostic process for prostate cancer typically involves a blood or biopsy test, followed by PET / CT imaging to visualise tumour, lymph nodes and any metastasis to help decide the treatment plan.

GalliProst provides a ‘heatmap’ style image, which displays the exact location and intensity of PSMA expressed on the surface of prostate cancer cells, said GE Healthcare.

GE Healthcare pharmaceutical diagnostics business Molecular Imaging Oncology global product leader Sanka Thiru said: “We believe that this partnership enables both parties to leverage each other’s key areas of expertise in order to accelerate the development of GalliProst and ultimately improve patient care.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In Phase II clinical study, Theragnostics’ imaging agent met the primary and secondary endpoints.

Data shows GalliProst scan led to a modification in treatment plans of around 33% of newly diagnosed patients and more than 50% of those with biochemically recurrent prostate cancer.

The company noted a 75% increase in patient management during post-radical radiotherapy setting.

Theragnostics CEO Greg Mullen said: “This agreement is the validation of the potential for our novel prostate cancer Gallium-68 (68Ga) diagnostic tracer, GalliProst which can benefit the treatment of prostate cancer patients around the globe.

“We are very pleased to sign our second agreement with GE Healthcare following our agreement last year for a diagnostic tracer for imaging kidney function and scarring.”